Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference

Antibody Drug Conjugate Technologies: 2023 West OncologyПодробнее

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2Подробнее

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in ReviewПодробнее

DESTINY-CRC02: antibody-drug conjugates in colorectal cancerПодробнее

Geriatric Oncology | 2023 West Oncology ConferenceПодробнее

Emerging toxicities associated with ADCsПодробнее

What Are Antibody Drug Conjugates? - OncTalk Lung 2023Подробнее

Antibody Drug Conjugates for CancerПодробнее

What are Antibody Drug Conjugates (ADCs)?Подробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

2022 West Oncology Conference | Breast Cancers | MetastaticПодробнее

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid TumorsПодробнее

Answers to Key Questions About Antibody–Drug Conjugates in NSCLCПодробнее

Antibody-drug conjugates for advanced bladder cancerПодробнее

Recent antibody-drug conjugate approvals in gynecologic malignanciesПодробнее

Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug ConjugatesПодробнее

New Hope in Cancer Treatment! What are Antibody-Drug Conjugates (ADCs)Подробнее

Antibody Drug Conjugates and Recent Applications in Breast Cancer TreatmentПодробнее